Myasthenia Gravis

Updated: Dec 11, 2017
  • Author: Abbas Jowkar, MD, MBBS, PA-C; Chief Editor: Nicholas Lorenzo, MD, MHA, CPE  more...
  • Print

Practice Essentials

Acquired myasthenia gravis (MG) is a relatively rare autoimmune disorder caused by an antibody-mediated blockade of neuromuscular transmission resulting in skeletal muscle weakness. The autoimmune attack occurs when autoantibodies form against the nicotinic acetylcholine postsynaptic receptors at the neuromuscular junction of skeletal muscles (see the image below). [1, 2] Although the chief target of the autoimmune attack in most cases is the skeletal muscle nicotinic acetylcholine recepter (nAChR), other antigenic targets that are components of the neuromuscular junction (NMJ) have also been implicated.

Normal neuromuscular junction showing a presynapti Normal neuromuscular junction showing a presynaptic terminal with a motor nerve ending in an enlargement (bouton terminale): Synaptic cleft and postsynaptic membrane with multiple folds and embedded with several acetylcholine receptors.

Signs and symptoms

The presentation of MG has the following characteristics:

  • The clinical hallmark of MG is the presence of fluctuating fatigable muscle weakness that worsens with activity and improves on rest
  • 50% to 85% of patients with MG present with ocular symptoms with or without generalized weakness
  • 50% to 60% of patients with MG who initially present with isolated ocular involvement go on to develop generalized weakness, often within 3 years after onset of symptoms
  • The disease remains exclusively ocular in only 15% to 25% of patients throughout their course [1, 2]
  • Approximately 20% of patients with MG may present with prominent bulbar symptoms
  • Bulbar muscle weakness is also common, along with weakness of head extension and flexion
  • Limb weakness may be more severe proximally than distally
  • Isolated limb muscle weakness is the presenting symptom in about 5% of patients [3]
  • Weakness progresses from mild to more severe over weeks or months, with exacerbations and remissions

The following factors may trigger or worsen exacerbations:

  • Warm weather
  • Surgery
  • Immunization
  • Emotional stress
  • Menstruation
  • Intercurrent illness (eg, viral infection)
  • Tapering of immunosuppression
  • Pregnancy and postpartum period
  • Worsening of chronic medical illnesses (cardiac, renal, autoimmune, etc.)
  • Medication (eg, aminoglycosides, ciprofloxacin, telithromycin. clindamycin, phenothiazines, chlorpromazine, diazepam, halothane, ketamine, lidocaine, procain, non-depolarizing neuromuscular blocking agents, chloroquine, procaine, lithium, phenytoin, beta-blockers, procainamide, propafenone, bretylium, qunidine, calcium channel blockers, d-penicillamine, high-dose prednisone, magneisum)

The Myasthenia Gravis Foundation of America Clinical Classification divides MG into 5 main classes and several subclasses [3] :

  • Class I: Any ocular muscle weakness; may have weakness of eye closure; all other muscle strength is normal
  • Class II: Mild weakness affecting other than ocular muscles; may also have ocular muscle weakness of any severity
    • Class IIa: Predominantly affecting limb, axial muscles, or both; may also have lesser involvement of oropharyngeal muscles
    • Class IIb: Predominantly affecting oropharyngeal, respiratory muscles, or both; may also have lesser or equal involvement of limb, axial muscles, or both
  • Class III: Moderate weakness affecting other than ocular muscles; may also have ocular muscle weakness of any severity
    • Class IIIa: Predominantly affecting limb, axial muscles, or both; may also have lesser involvement of oropharyngeal muscles
    • Class IIIb: Predominantly affecting oropharyngeal, respiratory muscles, or both; may also have lesser or equal involvement of limb, axial muscles, or both
  • Class IV: Severe weakness affecting other than ocular muscles; may also have ocular muscle weakness of any severity
    • Class IVa: Predominantly affecting limb, axial muscles, or both; may also have lesser involvement of oropharyngeal muscles
    • Class IVb: Predominantly affecting oropharyngeal, respiratory muscles, or both; may also have lesser or equal involvement of limb, axial muscles, or both
  • Class V: Defined by the need for intubation, with or without mechanical ventilation, except when used during routine postoperative management. The use of a feeding tube without intubation places the patient in class IVb.

See Clinical Presentation for more detail.


The anti–acetylcholine receptor (AChR) antibody test for diagnosing MG has the following characteristics:

  • High specificity (up to 100% [4] )
  • Positive in as many as 85% of patients who have generalized MG [4]
  • Positive in only 50% of patients who have purely ocular MG [4]

False-positive anti-AChR antibody test results have been reported in patients with the following:

  • Thymoma without MG
  • Lambert-Eaton myasthenic syndrome
  • Small cell lung cancer
  • Rheumatoid arthritis treated with penicillamine
  • 1-3% of the population older than 70 years

Assays for the following antibodies may also be useful:

  • Anti-MuSK antibody (present in about half of patients with negative results for anti-AChR antibody)
  • Anti-lipoprotein-related protein 4 (LRP4) antibody
  • Anti-agrin antibody
  • Antistriational antibody (present in almost all patients with thymoma and MG, as well as in half of MG patients with onset of MG at 50 years or older)
  • Anti-cortactin antibody

Other studies are as follows:

  • Plain chest radiographs may identify a thymoma as an anterior mediastinal mass
  • Chest computed tomography is important to identify or rule out thymoma or thymic enlargement in all cases of MG
  • In strictly ocular MG, magnetic resonance imaging of the brain and orbit is helpful to evaluate for mass lesions compressing the cranial nerves or a brainstem lesion that may masquerade as ocular MG
  • Electrodiagnostic studies (repetitive nerve stimulation and single-fiber electromyography)

See Workup for more detail.


Based on recent advances in understanding the various underlying antibodies that cause myasthenia gravis and differences in how they present clinically and their response to various therapies, it is suggested that patients with myasthenia gravis should be classified into subgroups. Subgroups are based on the profile of serum autantibodies, the age of onset, the presence or absence of thymic pathology, and the distribution of clinical weakness. [5]

Therapy for MG includes the following:

  • Symptomatic therapy
  • Anticholinesterase (AchE) inhibitors
  • Pyridostigmine is used for maintenance therapy [6, 7]
  • Neostigmine is generally used only when pyridostigmine is unavailable
  • Rapidly acting or short-term immunomodulating agents:
    • Intravenous immune globulin (IVIg)
  • Plasmapheresis
  • Long-term immunosuppression
    • Prednisone is the most important immunosuppressant and provides short- and long-term benefit.
    • Azathioprine (AZA) is a first-line steroid-sparing agent
    • Mycophenolate mofetil (MMF) is also a first-line steroid-sparing agent. It is widely used and less toxic than azathioprine.
    • Cyclosporine (CyA) is used as a steroid-sparing agent in patients who are intolerant to azathioprine and mycophenolate mofetil.
    • Tacrolimus is used as a steroid-sparing agent in patients intolerant or unresponsive to AZA, MMF, or CyA.
    • Methotrexate is used as a steroid-sparing agent and has similar efficacy and tolerability to AZA.
    • Rituximab may be an effective intervention in refractory MG, both for anti-AChR and anti-MuSK-positive disease.{ref5 [6, 7, 8]
    • Cyclophosphamide is used in refractory/severe MG.
  • Emerging novel therapies targeting immunopathogenesis of MG
    • Eculizumab is a humanized monoclonal IgG antibody against C5 complement.
    • Abatacept is a cytotoxic T-lymphocyte protein 4 (CTLA-4) monoclonal antibody, which binds to CD80/CD86 and blocks both activating (CD28) and inhibitory signals (CTLA-4).
    • Daclizumab is a monoclonal antibody that binds to CD25 thereby antagonizing the activating effects of IL-2 on T cells.
    • Belimumab binds to soluble B-cell activating factor (BAFF) and reduces B-cell activation and differentiation into antibody-producing plasma cells.
    • Bortezomib is a protease inhibitor that has shown experimental benefit in MG. It reduced anti-AChR antibody titers, inhibited damage to the postsynaptic muscle membrane, and resulted in clinical improvement. [9]
    • Fc receptor modulators (FcRn–IgG) in the form of monoclonal antibody is being studied in passive and active models of rat experimental MG and shown to ameliorate symptoms and lower autantibody levels. [10]
    • Several human monoclonal antibodies directed against IL-17 are in development, including brodalumab (AMG 827), ixekizumab (LY2439821), and secukinumab.
    • Toclizumab, a humanized monoclonal antibody targeting the IL-6 receptor, is being studied as a potential therapy.
    • Autologous stem cell transplantation has been proposed as a therapeutic approach for refractory autoimmune disease and is based on the idea that the transplanted immune cells will be “reset” and free of autoimmune reactivity. [11]
    • 3,4-Diaminopyridine is another symptomatic therapy with potential application in MuSK MG. Exploring use of this drug, which enhances AChR release at the motor nerve terminal, in MuSK MG is supported by preclinical models, experience with congenital MG with MuSK mutations, and case reports. [12, 13]
    • Tirasemtiv is a selective fast skeletal muscle troponin activator. This small molecule binds to skeletal muscle troponin, thereby sensitizing the muscle to calcium and ultimately improving muscle strength under submaximal stimulation. A study of tirasemtiv in experimental MG improved grip strength and muscle force after a single dose. [14]
  • Thymectomy
    • The Randomized Trial of Thymectomy in Myasthenia Gravis, a landmark study, has shown that trans-sternal thymectomy improves MG and even induces remission, or lessens the requirements or perhaps removes the need for prednisone and other immunosuppressants over a period of 3 years. [15]

See Treatment and Medication for more detail.

What is myasthenia gravis? Myasthenia gravis is an autoimmune disease that's categorized as a type II hypersensitivity that involves autoantibodies binding acetylcholine receptors on skeletal muscle cells. Video Attribution: Myasthenia Gravis by Osmosis is licensed under CC-BY-SA 4.0


Myasthenia gravis (MG) is a relatively rare autoimmune disorder in which antibodies form against nicotinic acetylcholine (ACh) postsynaptic receptors at the neuromuscular junction (NMJ) of the skeletal muscles. It is a type-II hypersensitivity immune response. The basic pathology is a reduction in the number of ACh receptors (AChRs) at the postsynaptic muscle membrane brought about by an acquired autoimmune reaction producing anti-AChR antibodies.

The reduction in the number of AChRs results in a characteristic pattern of progressively reduced muscle strength with repeated use and recovery of muscle strength after a period of rest. The ocular and bulbar muscles are affected most commonly and most severely, but most patients also develop some degree of fluctuating generalized weakness. [10] The most important aspect of MG in emergency situations is acute worsening of weakness leading to neuromuscular respiratory failure. The diagnosis of myasthenic versus cholinergic crisis and its management is also a significant challenge in emergent settings.

MG is a well-understood and well-managed disease. Pharmacologic therapy includes anticholinesterase agents, such as pyridostigmine, and immunosuppressive agents, such as corticosteroids, azathioprine, mycophenolate mofetil, tacrolimus, sirolimus, cyclosporine, cyclophosphamide, rituximab, plasmapheresis, and intravenous immune globulin (IVIg). Thymectomy has a significant role in the treatment of patients with generalized MG who are positive for acetylcholine receptor antibodies. Thymectomy becomes mandatory if a thymoma is present. Patients with MG require close follow-up care by a neurologist or neuromuscular specialist in cooperation with their primary care physician.



The neuromuscular junction (NMJ) serves as a transducer and amplifier to the peripheral nerve’s relatively small electrical current using a chemical signal subserved by neurotransmitter ACh. This in turn produces an electrical current of sufficient intensity and proper location such that it initiates a propagating action potential in the muscle fiber. Thus, the NMJ is considered an electrical-chemical-electrical link.

In MG, autoantibodies (immunoglobulin G [IgG]) develop against nicotinic acetylcholine postsynaptic receptors at the NMJ of skeletal muscles. [1, 2] The reasons for this development are unknown, although it is clear that certain genotypes are more susceptible. [11] To understand MG, it is necessary to become familiar with the normal anatomy and physiology of the NMJ (see the image below).

Normal neuromuscular junction showing a presynapti Normal neuromuscular junction showing a presynaptic terminal with a motor nerve ending in an enlargement (bouton terminale): Synaptic cleft and postsynaptic membrane with multiple folds and embedded with several acetylcholine receptors.

The nerve terminal of the motor nerve enlarges at its end to form the so-called terminal bouton or terminal bulb. This bulbous nerve terminal lies within a groove or indentation along the muscle fiber. The NMJ can be subdivided into 3 major areas: presynaptic, synpatic space, and post-synaptic regions. Disorders of neuromuscular transmission can arise from abnormalities in each of these locations.

The axon terminal (bouton) contains neurotubules and neurofilaments, multiple mitochondria for metabolic energy production, and a large number of membrane-bound vesicles ranging from 300 to 500 Angstrom units in diameter. These are called synaptic vesicles and each of these vesciles contain the neurotransmitter acetylcholine. Each vesicle contains approximately 1 quantum of acetylcholine, which equals 10,000 molecules of acetylcholine. These vesicles are organized in 3 discrete groups.

The primary, or immediately available store consists of approximately 1000 quanta of ACh located just beneath the pre-synaptic nerve terminal membrane and are located at specific sites called active zones. This store is available for immediate release. They behave like soldiers at the front line.

The secondary, or mobilization store consists of approximately 10,000 quanta of ACh that can resupply the primary store after a few seconds. They behave like immediate reinforcements.

Finally, a tertiary, or reserve store of more than 100,000 quanta exists far from the NMJ in the axon and cell body. They behave like the reserves.

In the resting state, these vesicles intermittently release quanta of ACh into the synaptic cleft, which is 50–75 nm wide. The released ACh diffuses across the primary synaptic cleft to bind on the AChR that are typically concentrated at the crests of postsynaptic folds opposite the presynaptic active zones. Secondary synaptic cleft (aka, subnerual clefts) are also a significant part of the post-synpatic membrane and located in the depths of the synaptic clefts are the voltage-gated sodium channels.

AChR is an ionotropic ligand-gated transmembrane receptor channel. It is a quaternary glycoprotein structure with 5 subunits surrounding a central cation channel with negatively charged inner wall. In the adult form of AChR (2α1ß1δ1ε) and in the fetal form of AChR (2α1ß1δ1γ). It has a half-life of 8-14 days. [16] These subunits are homologous across different species, suggesting that the encoding genes evolved from a common ancestral gene. The subunits are arranged in a circle, forming a central opening that acts as an ion channel (see the image below).

Acetylcholine receptor. Note 5 subunits, each with Acetylcholine receptor. Note 5 subunits, each with 4 membrane-spanning domains forming a rosette with a central opening. The central opening acts as an ion channel.

The post-synaptic membrane

The subunits in the AChRs are organized like barrel staves with their convexity inward or in an hourglass-like fashion. In the center is a cation channel. The ACh binding sites and the main immunogenic region (MIR) are located on the protruding extracellular surfaces of alpha subunits. These extracellular portions of AchR extend 100A units beyond the cell membrane. Sugars on the extracellular surface of the subunits extend outward and have complex branching patterns. On the cytoplasmic surface of the membrane are cytoskeletal components, which anchor the AChRs. The post-synaptic junctional folds are packed with AChRs (10,000 receptors/µm2) and also contain rapsyn, integrins, LRP4, MuSK, ErbB receptors, N-acetylgalactosaminlyl transferase, and collagen XIII. [17, 18] The troughs of the junctional folds have neural cell adhesion molecules (NCAM), and the voltage-gated sodium ion channels. The latter is tethered to Ankyrin G and β-spectrin, and are linked to the cytoskeleton by syntrophins. [19, 20] The cytoskeletal components also include utrophin and dystrophin, both of which are linked to dystrobrevin and syntrophin and via β- and α-dystroglycans to the extracellular matrix. Neureregulin is an isoform produced by the NR-1 gene. It is a motor nerve-derived trophic factor similar to agrin. It is thought to induce accumulation of voltage-gated sodium ion channels in the depths of the synaptic clefts. It is noted that shortly after neuregulin appears at the developing NMJ, fetal AChRs containing the γ-subunit (γ-AChRs) are replaced by adult AChRs containing the ε subunit (ε-AChRs). The ε subunit is dependent on the presence of neuregulin for its continued expression at the NMJ. [17]



In the resting state, there is an intermittent release of ACh molecules across the primary synaptic cleft. The ACh molecules serve as ligands and bind to the AChR on the post-synaptic membrane. Two molecules of ACh bind to the alpha subunits of the AChR, and fuse with it. The bound AChR then undergoes a 3-dimensional conformational change in the channel portion of the AChR (M2, alpha-helical) opening the funnel-shaped cation channel (whose inner wall is negatively charged) in the center of the AChR. This opening is very brief (about 1 ms) resulting in influx of sodium ions while simultaneously allowing potassium efflux along its opposite concentration gradient. This results in brief depolarization of the muscle membrane only at the junctional region creating a post-synaptic non-propagating depolarization called miniature endplate potentials (MEPPs).

The normal muscle fiber resting membrane potential is -80 mV (negative inside). The threshold for triggering an action potential in the muscle fiber is -50mV to -65mV. When a nerve action potential depolarizes the terminal axons, sodium ion conductance is increased and at the same time voltage-gated calcium channels (VGCCs) are activated, allowing an influx of calcium ion at the terminal portion of the axon. The entry of calcium ions is critical to the process of neuromuscular transmission (if Ca is removed from the extracellular space, NMJ transmission ceases). The entry of Ca ions starts a complicated interaction of many proteins including SNARE protein complex at the nerve terminal which facilitate fusion of the ACh-containing vesicles with the presynaptic membrane. Consequently, the discharge of ACh occurs by exocytosis into the synaptic cleft. The greater the calcium concentration inside the presynaptic terminal, the more quanta of ACh are released into the synaptic cleft.

ACh molecules bind to the AChRs resulting in a larger depolarization of the post-synaptic membrane resulting in the endplate potential (EPP). The amplitude of EPP is normally high enough to trigger an action potential at the post-synaptic membrane. The voltage-gated sodium channels present in the depths of the secondary synaptic cleft facilitate action potential, which is propagated along the NMJ muscle membrane. When this action potential invades the transverse tubule system of the muscle, another voltage-gated calcium channel (VGCC) becomes activated causing influx of calcium ions, and triggering mechanical contraction of the muscle fiber contractile apparatus.

The action of ACh on the post-synaptic membrane is short-lived and is terminated within a few milliseconds of its release from the nerve terminal through hydrolysis by the enzyme acetylcholinesterase. Acetic acid and choline form. The choline is taken up by the presynaptic membrane and repackaged into new ACh molecules.

The calcium ions are normally pumped out of the terminal portion of the axon within 100 ms, so they linger for a while and maintain the axon terminal in a hyperexcitable state, enhancing the release of ACh should a second action potential depolarizes the axon within this time frame.

Safety factor

The amplitude of the EPP tends to be >60 mV above the muscle fiber resting membrane potential of -80 mV.  So only 15mV is needed to reach the threshold for action potential of -65 mV. The extra 45 mV is referred as the Safety Factor. So, even if the EPP were to get smaller (e.g., 40 mV) due to repetitive contraction resulting in fatigue, the EPP would still be high to reach threshold and maintain the one-to-one relationship between the action potential of the motor axon and generation of an action potential in the muscle cell. However, if the safety factor is greatly decreased as it may occur in MG, this may lead to blocking of neuromuscular transmission.

In MG, the safety factor is reduced (i.e., baseline EPP is reduced but still above threshold). Slow RNS (3 Hz) will cause depletion of ACh quanta and may drop the EPP below threshold, resulting in the absence of a muscle fiber action potential (a phenomenon referred to as presynaptic rundown). Consequently, EPP is reduced as there are fewer AChRs for ACh molecules to bind.

In MG, there are anti-AChR-ab against AChR available at the post-synaptic folds, which become flattened or simplified by the immunpathology. This, on top of the gradual reduction of AChRs that are released with repeated use of the muscle, leads to insufficient endplate potentials (EPP), which may fall below the threshold value for generation of an action potential. The end result of this process is inefficient neuromuscular transmission. When this failure occurs at enough muscle fibers, it can manifest clinically and be demonstrated electrophysiologically through low-frequency repetitive nerve stimulation (3 Hz RNS). However, if it occurs in only a few muscle fibers it can be detected on single-fiber electromyography (SFEMG).

Patients become symptomatic once the number of AChRs is reduced to approximately 30% of normal. The cholinergic receptors of smooth and cardiac muscle have a different antigenicity than skeletal muscle and usually are not affected by the disease.

The decrease in the number of postsynaptic AChRs is believed to be due to an autoimmune process whereby anti-AChR antibodies are produced and block the target receptors, cause an increase the turnover of the receptors, and damage the postsynaptic membrane in a complement-mediated manner.

The exact mechanism of loss of immunologic tolerance to AChR, a self-antigen, is not understood. MG can be considered a B cell–mediated disease, in that it derives from antibodies (a B cell product) against AChR. However, the importance of T cells in the pathogenesis of MG is becoming increasingly apparent. The thymus is the central organ in T cell–mediated immunity, and thymic abnormalities such as thymic hyperplasia or thymoma are well recognized in myasthenic patients.

It is thought that both the initiation and maintenance of MG occurs in a process that involves type-II hypersensitivity reactions. Macrophages and dendritic cells are activated and these act as antigen-presenting cells. AChRs are phagocytized by macrophages and become degraded into peptide subcomponents. These are then linked to MHC-II, the molecule required for reactivity to “self-antigens.” The AChR antigenic fragment and MHC complex are transported to the surface of macrophages and dendritic cells. Specific, helper T cells, with the cooperation of CD3 complex and CD4 molecular T-cell receptor site, recognize this antigen complex. Specific receptor sites on the T-cell surface recognize cytokines secreted by the macrophage and dendritic cells. The activated helper T cells secrete substances that stimulate B lymphocytes. The activated B lymphocytes grow and undergo clonal expsansion into antibody-synthesizing plasma cells. These plasma cells secrete IgG anti-AChR antibodies that bind to the nictonic ACh-R.

Antibody response in MG is polyclonal. In an individual patient, antibodies are composed of different subclasses of IgG. In most instances, 1 antibody is directed against the main immunogenic region (MIR) on the alpha subunit. The alpha subunit is also the site of ACh binding, though the binding site for ACh is not always the same as the MIR. Binding of AChR antibodies to AChR results in impairment of neuromuscular transmission in several ways, including the following:

  • Cross-linking 2 adjacent AChRs with anti-AChR antibody, thus accelerating internalization and degradation of AChR molecules
  • Causing complement-mediated destruction of junctional folds of the postsynaptic membrane
  • Blocking the binding of ACh to AChR
  • Decreasing the number of AChRs at the NMJ by damaging the junctional folds on the postsynaptic membrane, thereby reducing the surface area available for insertion of newly synthesized AChRs

Patients without anti-AChR antibodies are recognized as having seronegative MG (SNMG). Many patients with SNMG have autoantibodies (IgG4) against muscle-specific kinase (MuSK). MuSK plays a critical role in postsynaptic differentiation and clustering of AChRs. Patients with anti-MuSK antibodies are predominantly women, with a tendency of disease onset in the third or fourth decades. They have prominent oculobulbar weakness with dysarthria. Face and tongeue atrophies have been reported in long-standing disease. It is often confused with bulbar amyotrophic lateral sclerosis (ALS). Another group has reported patients who exhibit prominent neck (dropped head syndrome), shoulder, and respiratory weakness. [12, 13]  Myasthenic crises appear to be more frequent in patients with MuSK antibodies. [21, 22]

The role of the thymus in the pathogenesis of MG is not entirely clear, but 75% of patients with MG have some degree of thymus abnormality (eg, hyperplasia or thymoma). Histopathologic studies have shown prominent germinal centers. Epithelial myoid cells normally present in the thymus do resemble skeletal muscle cells and possess AChRs on their surface membrane. These cells may become antigenic by molecular mimicry and unleash an autoimmune attack on the muscular endplate nicotinic AChRs.

The question of why MG affects the extraocular muscles first and predominantly remains unanswered. The answer probably has to do with type and distribution of NMJs in at least some of the muscles affected by the disease.

The distinctive features in MG, particularly the fluctuating nature of a patient's strength, is attributed to the unique pathophysiology of impaired neuromuscular transmission. This pathophysiology produces a dynamic rather than a fixed disorder as a result of the relative ease by which NMJs repair.



MG is idiopathic in most patients. Although the main cause behind its development remains speculative, the end result is a derangement of immune system regulation. MG is clearly an autoimmune disease in which the specific antibody has been characterized completely. In as many as 90% of generalized cases, IgG to AChR is present. [14] Even in patients who do not develop clinical myasthenia, anti-AChR antibodies can sometimes be demonstrated.

Patients who are negative for anti-AChR antibodies may be seropositive for antibodies against MuSK. Muscle biopsies of these patients show myopathic features with prominent mitochondrial abnormalities, as opposed to the neurogenic features and atrophy frequently found in MG patients positive for anti-AChR. The mitochondrial impairment could explain the oculobulbar involvement in anti-MuSK–positive MG. [23]

Numerous findings have been associated with MG. For example, people with certain human leukocyte antigen (HLA) types have a genetic predisposition to autoimmune diseases. The histocompatibility complex profile includes HLA-A1, -A3, -B7, -B8, -DRw3, and -DQw2 (though these have not been shown to be associated with the strictly ocular form of MG). However, HLA genotyping is not routinely used in the evaluation of patients suspected to have MG.

Sensitization to a foreign antigen that has cross-reactivity with the nicotinic ACh receptor has been proposed as a cause of myasthenia gravis, but the triggering antigen has not yet been identified.

Various drugs may induce or exacerbate symptoms of MG, including the following:

  • Antibiotics (eg, aminoglycosides, polymyxins, ciprofloxacin, erythromycin, and ampicillin)
  • Penicillamine - This can induce true myasthenia, with elevated anti-AChR antibody titers seen in 90% of cases; however, the weakness is mild, and full recovery is achieved weeks to months after discontinuance of the drug
  • Beta-adrenergic receptor blocking agents (eg, propranolol and oxprenolol)
  • Lithium
  • Magnesium
  • Procainamide
  • Verapamil
  • Quinidine
  • Chloroquine
  • Prednisone
  • Timolol (ie, a topical beta-blocking agent used for glaucoma)
  • Anticholinergics (eg, trihexyphenidyl)
  • Neuromuscular blocking agents (eg, vecuronium and curare) - These should be used cautiously in myasthenic patients to avoid prolonged neuromuscular blockade

Nitrofurantoin has also been linked to the development of ocular MG in 1 case report; discontinuance of the drug resulted in complete recovery.

Thymic abnormalities are common: Of patients with MG, 75% have thymic disease, 85% have thymic hyperplasia, and 10-15% have thymoma. Extrathymic tumors may include small cell lung cancer and Hodgkin disease. [24, 25] Hyperthyroidism is present in 3-8% of patients with MG and has a particular association with ocular MG.



The overall incidence rate of MG has been estimated at 2.1 to 5.0 per million people per year and has not changed over time. However, the prevalence rate has increased since the 1950s in keeping with the declining mortality rate in MG. [23, 24]

Approximately 15%–20% of patients with MG experience crisis in their lifetime, typically within the first 2 years of the diagnosis. [25]

Fifty years ago, estimates of mortality in MG crisis ranged from 50% to 80%. [26, 27, 28] Currently, the overall in-hospital mortality rate was 2.2%, being higher in MG crisis (4.47%). Older age and respiratory failure were the predictors of death.

Age-related demographics

MG can occur at any age. Female incidence peaks in the third decade of life, whereas male incidence peaks in the sixth or seventh decade. The mean age of onset is 28 years in females and 42 years in males.

Transient neonatal MG occurs in infants of myasthenic mothers who acquire anti-AChR antibodies via placental transfer of IgG. Some of these infants may suffer from transient neonatal myasthenia due to effects of these antibodies.

Most infants born to myasthenic mothers possess anti-AChR antibodies at birth, yet only 10-20% develop neonatal MG. This may be due to protective effects of alpha-fetoprotein, which inhibits binding of anti-AChR antibody to AChR. High maternal serum levels of AChR antibody may increase the chance of neonatal MG; thus, lowering the maternal serum titer during the antenatal period by means of plasmapheresis may be useful.

Sex-related demographics

Classically, the overall female-to-male ratio has been considered to be 3:2, with a female predominance in younger adults (ie, patients aged 20-30 years) and a slight male predominance in older adults (ie, patients older than 50 years). [6, 10] Studies show, however, that with increased life expectancy, males are coming to be affected at the same rate as females. Ocular MG shows a male preponderance. The male-to-female ratio in children with MG and another autoimmune condition is 1:5.

Race-related demographics

The onset of MG at a young age is slightly more common in Asians than in other races. [6]

The annual incidence rate of MG is higher in black women (0.01 per 1000 persons/year) compared to white women (0.009 per 1000 persons/year) and white (0.008 per 1000 persons/year) and black men (0.007 per 1000 persons/year). [29]

MG can be classified by age of onset, site or sites of involvement on the NMJ, serological status, and associated thymic pathology. This is helpful in diagnosis and management. Also, the sensitivity of diagnostic tests may very according to age of onset, specific antibodies, and whether the disease is ocular or generalized.

The vast majority of patients have MG that is immune mediated, but they are very rare congenital myasathenic syndromes that have no immune basis and where immunosuppresants must not be used.



Given current treatment, which combines cholinesterase inhibitors, immunosuppressive drugs, plasmapheresis, immunotherapy, and supportive care in an intensive care unit (ICU) setting (when appropriate), most patients with MG have a near-normal life span. Mortality is now 3-4%, with principal risk factors being age older than 40 years, short history of progressive disease, and thymoma; previously, it was as high as 30-40%. In most cases, the term gravis is now a misnomer.

Morbidity results from intermittent impairment of muscle strength, which may cause aspiration, increased incidence of pneumonia, falls, and even respiratory failure if not treated. [14] In addition, the medications used to control the disease may produce adverse effects.

Today, the only feared condition arises when the weakness involves the respiratory muscles. Weakness might become so severe as to require ventilatory assistance. Those patients are said to be in myasthenic crisis.

The disease frequently presents (40%) with only ocular symptoms. However, the extraocular almost always are involved within the first year. Of patients who show only ocular involvement at the onset of MG, only 16% still have exclusively ocular disease at the end of 2 years.

In patients with generalized weakness, the nadir of maximal weakness usually is reached within the first 3 years of the disease. As a result, half of the disease-related mortality also occurs during this period. Those who survive the first 3 years of disease usually achieve a steady state or improve. Worsening of disease is uncommon after 3 years.

Thymectomy results in complete remission of the disease in a number of patients. However, the prognosis is highly variable, ranging from remission to death.


Patient Education

Educate patients to recognize and immediately report impending respiratory crisis. Intercurrent infection may worsen symptoms of MG temporarily. Mild exacerbation of weakness is possible in hot weather.

The risk of congenital deformity (arthrogryposis multiplex) is increased in offspring of women with severe MG. Neonates born to women with MG must be monitored for respiratory failure for 1-2 weeks after birth. Certain immunosuppressant drugs have teratogenic potential. Discuss these aspects with women in reproductive years before beginning therapy with these drugs.

Certain medications (eg, aminoglycosides, ciprofloxacin, chloroquine, procaine, lithium, phenytoin, beta-blockers, procainamide, and quinidine) may exacerbate symptoms of MG; many others have been associated only rarely with exacerbation of MG. Patients should always consult a neurologist before starting any of these medications.